Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026
|
A05948
|
Pages: 250
|
Jan
2020 |
3275 Views
|
|
|
|
Author(s) :
Sayali Shinde
, Onkar Sumant
|
Tables: 114
|
Charts: 43
|
Formats*:
|
|
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Irritable Bowel Syndrome Treatment Market
Request Now !Irritable Bowel Syndrome Treatment Market Overview: 2026
The irritable bowel syndrome treatment market size was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026.
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine. Signs & symptoms include abdominal pain, bloating, gas, cramping, and constipation or diarrhea. There are three types of irritable bowel syndrome such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. Treatment of irritable bowel syndrome consist of stress relief, change in diet, proper medicines, and counselling. Medications available for the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others. Furthermore, antispasmodics are also used for the treatment of irritable bowel syndrome, which include dicyclomine, peppermint oil, and hyoscyamine.
Get more information on this report : Request Sample Pages
Rise in geriatric population, increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit and abdominal pain, surge in level of stress, and unhealthy diet are the major factors that drive the growth of the irritable bowel syndrome treatment market. In addition, increase in awareness programs regarding the treatment and management of irritable bowel syndrome and surge in inclination toward IBS products that enhance therapeutic outcome are other factors that contribute toward the growth of the market. Furthermore, untapped potential offered by the developing economies present lucrative opportunities for the growth of the market during the forecast period. However, lack of specific treatment that treat all the symptoms of the IBS disorder and high competition among the key players related to pricing are expected to restrain the growth of the market.
Irritable Bowel Syndrome Treatment Market Segmentation
The irritable bowel syndrome treatment market is segmented into type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. On the basis of product, the market is bifurcated into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. On the basis of end user, the market is divided into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the irritable bowel syndrome treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Review
Based on type, the market is segmented into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. The IBS with diarrhea (IBS-D) segment acquired the largest irritable bowel syndrome treatment market share in 2018. Furthermore, this segment is also expected to experience growth at the fastest rate during the forecast period, owing to increase in prevalence of gastrointestinal diseases such as constipation and diarrhea due to change in lifestyles, increase in geriatric population, surge in uptake of drugs such as linaclotide and lubiprostone, and rise in patient awareness toward the treatment of irritable bowel syndrome.
Irritable Bowel Syndrome Treatment Market
By Type
IBS With Diarrhea is projected as one of the most lucrative segment.
Get more information on this report : Request Sample Pages
According to product, the rifaximin segment generated the highest revenue in 2018 and is expected to maintain its dominance throughout the forecast period. This is attributed to increase in prevalence of irritable bowel syndrome, surge in adoption of the irritable bowel syndrome products, rise in geriatric population, increase in awareness toward irritable bowel syndrome and improved diagnosis, and development of technological advanced treatment products that has driven the demand for use of irritable bowel syndrome treatment market products worldwide.
Irritable Bowel Syndrome Treatment Market
By Product
Rifaximin holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Get more information on this report : Request Sample Pages
Snapshot of Asia-Pacific Irritable Bowel Syndrome Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the irritable bowel syndrome treatment market, growth in awareness regarding the treatment of irritable bowel syndrome, and rise in adoption of irritable bowel syndrome treatment products. Moreover, improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contributes to the market growth. Some other factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, high population base, and high disposable incomes are expected to drive the growth of the irritable bowel syndrome treatment market in Asia-Pacific.
Irritable Bowel Syndrome Treatment Market
By Geography
Asia-Pacific region would exhibit the highest CAGR of 9.9% during 2019-2026.
Get more information on this report : Request Sample Pages
The key players profiled in this report include Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., and Takeda Pharmaceutical Company Ltd.
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the irritable bowel syndrome treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers irritable bowel syndrome treatment market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global irritable bowel syndrome treatment market growth.
Key Market Segments:
By Type
- IBS with Diarrhea (IBS-D)
- IBS with Constipation (IBS-C)
- Mixed IBS
By Product
- Rifaximin
- Eluxadoline
- Lubiprostone
- Linaclotide
- Others
By End User
- Hospitals Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in geriatric population
3.4.1.2. Rise in prevalence of gastrointestinal disorders
3.4.1.3. Increase in number of pipeline drugs
3.4.2. Restrains
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunities
3.4.3.1. Untapped opportunities in developing economies
3.4.4. Impact analysis
CHAPTER 4: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. IBS with Diarrhea (IBS-D)
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. IBS with Constipation (IBS-C)
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Mixed-presentation IBS (IBS-M)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT
5.1. Overview
5.1.1. Market size and forecast
5.2. Rifaximin
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Eluxadoline
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Lubiprostone
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Linaclotide
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
CHAPTER 6: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online pharmacies
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. irritable bowel syndrome treatment market, by type
7.2.2.1.2. U.S. irritable bowel syndrome treatment market, by product
7.2.2.1.3. U.S. irritable bowel syndrome treatment market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada irritable bowel syndrome treatment market, by type
7.2.2.2.2. Canada irritable bowel syndrome treatment market, by product
7.2.2.2.3. Canada irritable bowel syndrome treatment market, by end user
7.2.2.3. Mexico
7.2.2.3.1. Mexico irritable bowel syndrome treatment market, by type
7.2.2.3.2. Mexico irritable bowel syndrome treatment market, by product
7.2.2.3.3. Mexico irritable bowel syndrome treatment market, by end user
7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by product
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany irritable bowel syndrome treatment market, by type
7.3.2.1.2. Germany irritable bowel syndrome treatment market, by product
7.3.2.1.3. Germany irritable bowel syndrome treatment market, by end user
7.3.2.2. France
7.3.2.2.1. France irritable bowel syndrome treatment market, by type
7.3.2.2.2. France irritable bowel syndrome treatment market, by product
7.3.2.2.3. France irritable bowel syndrome treatment market, by end user
7.3.2.3. UK
7.3.2.3.1. UK irritable bowel syndrome treatment market, by type
7.3.2.3.2. UK irritable bowel syndrome treatment market, by product
7.3.2.3.3. UK irritable bowel syndrome treatment market, by end user
7.3.2.4. Italy
7.3.2.4.1. Italy irritable bowel syndrome treatment market, by type
7.3.2.4.2. Italy irritable bowel syndrome treatment market, by product
7.3.2.4.3. Italy irritable bowel syndrome treatment market, by end user
7.3.2.5. Spain
7.3.2.5.1. Spain irritable bowel syndrome treatment market, by type
7.3.2.5.2. Spain irritable bowel syndrome treatment market, by product
7.3.2.5.3. Spain irritable bowel syndrome treatment market, by end user
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe irritable bowel syndrome treatment market, by type
7.3.2.6.2. Rest of Europe irritable bowel syndrome treatment market, by product
7.3.2.6.3. Rest of Europe irritable bowel syndrome treatment market, by end user
7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by product
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan irritable bowel syndrome treatment market, by type
7.4.2.1.2. Japan irritable bowel syndrome treatment market, by product
7.4.2.1.3. Japan irritable bowel syndrome treatment market, by end user
7.4.2.2. China
7.4.2.2.1. China irritable bowel syndrome treatment market, by type
7.4.2.2.2. China irritable bowel syndrome treatment market, by product
7.4.2.2.3. China irritable bowel syndrome treatment market, by end user
7.4.2.3. Australia
7.4.2.3.1. Australia irritable bowel syndrome treatment market, by type
7.4.2.3.2. Australia irritable bowel syndrome treatment market, by product
7.4.2.3.3. Australia irritable bowel syndrome treatment market, by end user
7.4.2.4. India
7.4.2.4.1. India irritable bowel syndrome treatment market, by type
7.4.2.4.2. India irritable bowel syndrome treatment market, by product
7.4.2.4.3. India irritable bowel syndrome treatment market, by end user
7.4.2.5. South Korea
7.4.2.5.1. South Korea irritable bowel syndrome treatment market, by type
7.4.2.5.2. South Korea irritable bowel syndrome treatment market, by product
7.4.2.5.3. South Korea irritable bowel syndrome treatment market, by end user
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific irritable bowel syndrome treatment market, by type
7.4.2.6.2. Rest of Asia-Pacific irritable bowel syndrome treatment market, by product
7.4.2.6.3. Rest of Asia-Pacific irritable bowel syndrome treatment market, by end user
7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by product
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil irritable bowel syndrome treatment market, by type
7.5.2.1.2. Brazil irritable bowel syndrome treatment market, by product
7.5.2.1.3. Brazil irritable bowel syndrome treatment market, by end user
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia irritable bowel syndrome treatment market, by type
7.5.2.2.2. Saudi Arabia irritable bowel syndrome treatment market, by product
7.5.2.2.3. Saudi Arabia irritable bowel syndrome treatment market, by end user
7.5.2.3. South Africa
7.5.2.3.1. South Africa irritable bowel syndrome treatment market, by type
7.5.2.3.2. South Africa irritable bowel syndrome treatment market, by product
7.5.2.3.3. South Africa irritable bowel syndrome treatment market, by end user
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA irritable bowel syndrome treatment market, by type
7.5.2.4.2. Rest of LAMEA irritable bowel syndrome treatment market, by product
7.5.2.4.3. Rest of LAMEA irritable bowel syndrome treatment market, by end user
7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by product
7.5.5. LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Allergan plc
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Ardelyx Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Astellas Pharma Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. AstraZeneca plc
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. GlaxoSmithKline Plc
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Johnson & Johnson (McNeil Consumer Healthcare)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Sebela Pharmaceuticals Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. Takeda Pharmaceutical Company Ltd.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 02. IBS WITH DIARRHEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. IBS WITH CONSTIPATION IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, (2018–2026 ($MILLION)
TABLE 04. MIXED IBS IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 06. RIFAXIMIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. ELUXADOLINE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. LUBIPROSTONE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. LINACLOTIDE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. OTHERS GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 12. IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 13. IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 14. IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 15. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17. U.S. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 18. U.S. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 19. U.S. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 20. CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 21. CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 22. CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 23. MEXICO IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 24. MEXICO IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 25. MEXICO IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 26. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 27. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 28. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 29. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 30. GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 31. GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 32. GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 33. FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 34. FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 35. FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 36. UK IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 37. UK IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 38. UK IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 39. ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 40. ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 41. ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 42. SPAIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 43. SPAIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 44. SPAIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 45. REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 46. REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 47. REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 48. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 49. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 50. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 51. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52. JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 53. JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 54. JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 55. CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 56. CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 57. CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 58. AUSTRALIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 59. AUSTRALIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 60. AUSTRALIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 61. INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 62. INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 63. INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 64. SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 65. SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 66. SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 67. REST OF ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 68. REST OF ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 69. REST OF ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 70. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 71. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 72. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 73. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 74. BRAZIL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 75. BRAZIL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 76. BRAZIL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 77. SAUDI ARABIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 78. SAUDI ARABIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 79. SAUDI ARABIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 80. SOUTH AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 81. SOUTH AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 82. SOUTH AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 83. REST OF LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 84. REST OF LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 85. REST OF LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 86. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 87. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 88. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 89. ABBOTT: COMPANY SNAPSHOT
TABLE 90. ABBOTT: OPERATING SEGMENTS
TABLE 91. ABBOTT: PRODUCT PORTFOLIO
TABLE 92. ALLERGAN: COMPANY SNAPSHOT
TABLE 93. ALLERGAN: OPERATING SEGMENTS
TABLE 94. ALLERGAN: PRODUCT PORTFOLIO
TABLE 95. ARDELYX: COMPANY SNAPSHOT
TABLE 96. ARDELYX: PRODUCT PORTFOLIO
TABLE 97. ASTELLAS: COMPANY SNAPSHOT
TABLE 98. ASTELLAS: PRODUCT PORTFOLIO
TABLE 99. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 100. ASTRAZENECA: OPERATING SEGMENTS
TABLE 101. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 102. GSK: COMPANY SNAPSHOT
TABLE 103. GSK: OPERATING SEGMENTS
TABLE 104. GSK: PRODUCT PORTFOLIO
TABLE 105. J&J: COMPANY SNAPSHOT
TABLE 106. J&J: OPERATING SEGMENTS
TABLE 107. J&J: PRODUCT PORTFOLIO
TABLE 108. NOVARTIS: COMPANY SNAPSHOT
TABLE 109. NOVARTIS: OPERATING SEGMENTS
TABLE 110. NOVARTIS: PRODUCT PORTFOLIO
TABLE 111. SEBELA: COMPANY SNAPSHOT
TABLE 112. SEBELA: PRODUCT PORTFOLIO
TABLE 113. TAKEDA: COMPANY SNAPSHOT
TABLE 114. TAKEDA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. MODERATE THREAT OF SUBSTITUTES
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE INTENSITY OF RIVALRY
FIGURE 08. IMPACT ANALYSIS
FIGURE 09. COMPARATIVE ANALYSIS OF IBS WITH DIARRHEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF IBS WITH CONSTIPATION IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF MIXED IBS IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF RIFAXIMIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF ELUXADOLINE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF LUBIPROSTONE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF LINACLOTIDE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF OTHERS IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 20. ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 22. ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23. ALLERGAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 24. ALLERGAN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 25. ARDELYX: NET SALES, 2017–2018 ($MILLION)
FIGURE 26. ARDELYX: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 27. ASTELLAS: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. ASTELLAS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29. ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 30. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 31. ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 32. ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 33. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 34. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 35. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 36. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42. TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. TAKEDA: REVENUE SHARE BY REGION, 2018 (%)
Irritable bowel syndrome treatment products relieves the patient from the gastrointestinal disorder symptoms and improves the quality of life. Diagnosis of irritable bowel syndrome is done by tests such as stool tests, blood tests, external imaging procedures, and endoscopic procedures. Treatment of irritable bowel syndrome include change in diet, stress relief, proper medicines, and counseling.
Increase in geriatric population, adoption of sedentary lifestyle, surge in level of stress and unhealthy diet, increase in prevalence of gastrointestinal diseases and disorders, rise in awareness programs for irritable bowel syndrome treatment significantly boost the growth of the irritable bowel syndrome treatment market. Moreover, launches of various developed pipeline drugs for the irritable bowel syndrome treatment and rise in awareness programs further boost the market growth. However, high competition among the key players related to pricing hinders the market growth.
North America is expected to remain dominant during the forecast period due to higher adoption of irritable bowel syndrome treatment products with increase in number of pipeline drugs, large presence of pharmaceutical, and R&D laboratories. In addition, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period due to developments in R&D and pharmaceutical sectors along with rise in demand for irritable bowel syndrome treatment products.
Q1. What is the total market value of irritable bowel syndrome treatment market report ?
A. The market value of global irritable bowel syndrome treatment market was $1,070.5 million in 2018.
Q2. What would be forecast period in the market report?
A. The forecast period is from 2019 to 2026.
Q3. What is the market value of irritable bowel syndrome treatment market in 2019?
A. The market value of global irritable bowel syndrome treatment market in 2019 is $1,159.3 million.
Q4. What are the Key Industry Leaders opinion for the irritable bowel syndrome treatment market?
A. The adoption of irritable bowel syndrome treatment is expected to significant increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, abdominal pain, adoption of sedentary lifestyle, increase in level of stress, and unhealthy diet majorly driving the market growth
Q5. Which is base year calculated in the irritable bowel syndrome treatment market report
A. The base year calculated in the report is 2018.
Q6. Does the Allergan plc company is profiled in the report?
A. Yes, Allergan plc is profiled in the report.
Q7. What are the market values / growth % of emerging countries?
A. Emerging countries of Asia-Pacific region are growing at a growth% of 9.9%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 9.8%, 11.0%, 9.1%, 10.6%, 9.4% respectively.
Q8. Which market holds the maximum market share of the irritable bowel syndrome treatment market?
A. The North America market held a major share in the irritable bowel syndrome treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to development of technological advanced treatment products, increased adoption of irritable bowel syndrome treatment products for the treatment of gastrointestinal disorders, rise in patient awareness toward irritable bowel syndrome treatment, increase in incidences of gastrointestinal diseases, and rise in geriatric population are driving the irritable bowel syndrome treatment market in North America
Download Sample
Purchase Full Report of
Irritable Bowel Syndrome Treatment Market
- Online Only
- $3,456
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3,840
- Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5,769
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6,450
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8,995
- Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading instantly.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.